Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Citation
Husain M, Bain SC, Jeppesen OK, et al. Diabetes Obes Metab 2020;22:442–51.